Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea

Diabetes Care

Volumn 29, Issue 11, 2006, Pages 2371-2377

  Triplitt, Curtis ^a   Glass, Leonard ^a   Miyazaki, Yoshiniro ^a   Wajcberg, Estela ^a   Gastaldelli, Amalia ^a   De Filippis, Elena ^a   Cersosimo, Eugenio ^a   DeFronzo, Ralph A ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; EDEMA; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 33845478593     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0564     Document Type: Article

References (37)

1. Ohkubo Y, Ishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
2. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854-865, 1998
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
4. DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
5. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL: Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103:491-497, 1997
6. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT: Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials: the Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 20:597-606, 1997
7. Rosenstock J, Samols E, Muchmore DB, Schneider J: Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients: Glimepiride Study Group. Diabetes Care 19:1194-1199, 1996
8. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
9. Herman LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A: Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 17:1100-1109, 1994
10. Aljabri K, Kozak SE, Thompson DM: Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 116:230-235, 2004
11. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G: Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin naïve patients. Diabetes Care 29:554-559, 2006
12. Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL: The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: a multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:737-745, 2001
13. Shank M, Del Prato S, DeFronzo RA: Bedtime insulin-daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes 44:165-172, 1995
14. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M: Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 130:389-396, 1999
15. Chow CC, Tsang LW, Sorenson JP, Cockram CS: Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 18:307-314, 1995
16. DeFronzo RA: Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177-269, 1997
17. DeFronzo RA, Ferrannini E, Simonson DC: Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387-395, 1989
18. Luzio SD, Beck P, Owens DR: Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with type 2 diabetes. Horm Metab Res 35:434-438, 2003
19. Yki-Jarvinen H, Dressler A, Ziemen M: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes: HOE 901/3002 Study Group. Diabetes Care 23:1130-1136, 2000
20. DeFronzo R, Tobin J, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
21. Steele R: Influence of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420-430, 1959
22. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, De-Fronzo RA: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest 84:205-213, 1989
23. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470, 1999
24. Hume R, Weyers E: Relationship between total body water and surface area in normal and obese subjects. J Clin Pathol 24:234-238, 1971
25. Wysowski DK, Armstrong G, Governale L: Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care 26:1852-1855, 2003
26. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS: Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 88:3598-3604, 2003
27. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091, 2005
28. Riddle MC, Rosenstock J, Gerich J, the Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-3086, 2003
29. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
30. Natali A, Ferrannini E: Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49:434-441, 2006
31. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219, 2001
32. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791, 2002
33. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA: Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89:200-206, 2004
34. Bays H, Mandarino L, DeFronzo RA: Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478, 2004
35. Gerhold DL, Liu F, Jiang G, Li Z, Xu J, Lu M, Sachs JR, Bagchi A, Fridman A, Holder DJ, Doebber TW, Berger J, Elbrecht A, Moller DE, Zhang BB: Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrinology 143:2106-2118, 2002
36. Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA: Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 37:1025-1035, 1994
37. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM: Insulin therapy in obese, non-insulin-dependent diabetes induces improvement in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33:634-642, 1984